To those who ask if Pfizer Inc.'s proposed $68 billion acquisition of Wyeth represents the same kind of short-term remedy as the company's past megadeals, CEO Jeff Kindler (pictured) has been giving a consistent answer: We're different now.
Kindler expanded on the theme
in an interview with The Associated Press that ran over the weekend. Touting a reorg over the last two years that has tied R&D into business units, he said Pfizer couldn't have done a deal like this a year ago.
In a
previous post we touched on the challenges of laying off some people while retaining others -- and keeping productivity up.
Kindler says the biz unit structure is the key: "Each of those units can conduct an integration that is much more manageable in size and scope than if you were just looking at the entire two companies." -
Kenneth Klee
Join Corporate Dealmaker's LinkedIn forum
Juergen Lasowski
And the winners are...
